One approach to develop drugs for infectious diseases involves a comprehensive understanding of human-pathogen protein interactions, as targeting host proteins helps reduce the possibility of drug resistance by creating a more significant evolutionary barrier for the virus.
One of the challenges with this approach comes when validating candidates from virus-host protein interaction studies, as multiple potential host factors must be screened in parallel using CRISPR screens that are difficult to perform due to scale, bandwidth and time constraint limitations.
Download this case study to learn more about:
- The use of Engineered Cell Libraries in host-virus interaction studies
- The development of genome engineering screens
- Data from CRISPR knockout screens and downstream assays showing functional and clinical relevance of targets validated